Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
NVO
Novo Nordisk A/S Com
$49.78
Chart
$65.3 (-23.77%)
$67.02 (-25.72%)
$76.86 (-35.23%)
$135.18 (-63.18%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
NVO
Novo Nordisk A/S Com
Current Price
$49.78
Login to view Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
Chart
$65.3 (-23.77%)
$67.02 (-25.72%)
$76.86 (-35.23%)
$135.18 (-63.18%)
NVO Latest Analysis
Hims & Hers Remains Outside Novo Nordisks Growing Legal Storm For Now. ) has been one of 2025’.s hottest telehealth stocks nearly doubling in value year to date but a deepening clash with ) over compounded weight-loss drugs and shifting FDA rules has turned momentum into headwinds sending shares sliding 10% in the past three months.The telehealth company’.s stock has surged to almost . However over the last three months the stock has fallen around 10%. In June the stock cratered almost
Today
The Zacks Analyst Blog Highlights Pfizer Novo Nordisk and Eli Lilly. Pfizer beats Q2 estimates with rising oncology sales new drug launches and strong Seagen-driven portfolio growth.
Today
Is the Market ish or Bearish on Novo Nordisk?. ) short percent of float has fallen 7.89% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Mon Aug 11, 2025
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes.
Mon Aug 11, 2025
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities.
Mon Aug 11, 2025
Why Novo Nordisk Stock Flew Higher on Friday. Key PointsAn archrivals investigational obesity drug didnt perform spectacularly in a recent clinical study.
Fri Aug 8, 2025
SHAREHOLDER ACTION REMINDER: Faruqi &. Faruqi LLP Investigates Claims on Behalf of Investors of Novo Nordisk. Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7 2025 to July 28 2025 and would like to discuss your...
Fri Aug 8, 2025
European shares on track for biggest weekly gain in 12. Novo Nordisk rises . European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed United States President Donald Trumps nomination for Federal Reserves open spot on its governing board.
Fri Aug 8, 2025
Novo Nordisk: More Pain On The Horizon.
Thu Aug 7, 2025
Novo Nordisk Q2 Earnings Beat Sales Miss GLP-1 Drugs Face US Hurdles. NVOs Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face United States setbacks and rising competition.
Wed Aug 6, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings